Blackstone Inc. purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 2,070,684 shares of the company's stock, valued at approximately $6,730,000. Blackstone Inc. owned about 2.99% of Inhibikase Therapeutics as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Stifel Financial Corp purchased a new stake in Inhibikase Therapeutics during the fourth quarter valued at approximately $43,000. Alpine Global Management LLC bought a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at $48,000. Caxton Corp purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter worth $53,000. Northern Trust Corp bought a new position in Inhibikase Therapeutics in the 4th quarter worth $208,000. Finally, Barclays PLC purchased a new position in Inhibikase Therapeutics during the fourth quarter valued at $273,000. Institutional investors own 3.81% of the company's stock.
Inhibikase Therapeutics Price Performance
IKT opened at $2.09 on Tuesday. The firm has a market cap of $155.37 million, a P/E ratio of -0.78 and a beta of 1.01. Inhibikase Therapeutics, Inc. has a 1-year low of $1.12 and a 1-year high of $4.20. The company has a 50 day simple moving average of $2.13 and a two-hundred day simple moving average of $2.52.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "neutral" rating on shares of Inhibikase Therapeutics in a research report on Friday, March 28th.
Check Out Our Latest Stock Analysis on IKT
Inhibikase Therapeutics Company Profile
(
Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
